By Elaine Rigoli
Tampa, Fla., Aug. 7 - NanoBio Corp. said Monday that it secured a $30 million equity investment from Perseus, LLC and said the funding, which will come in three tranches, will support NanoBio's expanding clinical pipeline.
NanoBio has developed multiple topical anti-infective products and vaccine candidates derived from its patented NanoStat technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores) and onychomycosis (nail fungus) and a mucosal vaccine for influenza.
NanoBio is a private biopharmaceutical company with headquarters in Ann Arbor, Mich.
Perseus is a private equity-fund management company with headquarters in Washington, D.C.
| Issuer: | NanoBio Corp.
|
| Issue: | Private equity financing
|
| Amount: | $30 million
|
| Investors: | Perseus, LLC
|
| Announcement date: | Aug. 7
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
